MURA Fundamental Analysis - MURAL ONCOLOGY PLC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to MURA. MURA was compared to 541 industry peers in the Biotechnology industry. MURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MURA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MURA has reported negative net income.

In the past year MURA has reported a negative cash flow from operations.

1.2 Ratios

Looking at the Return On Assets, with a value of -168.07%, MURA is doing worse than 87.99% of the companies in the same industry.

MURA has a Return On Equity of -250.33%. This is in the lower half of the industry: MURA underperforms 69.69% of its industry peers.

		Industry Rank	Sector Rank
ROA	-168.07%
ROE	-250.33%
ROIC	N/A

ROA(3y)-235.67%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MURA has more shares outstanding than it did 1 year ago.

MURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -7.48, we must say that MURA is in the distress zone and has some risk of bankruptcy.

MURA has a Altman-Z score of -7.48. This is in the lower half of the industry: MURA underperforms 67.65% of its industry peers.

There is no outstanding debt for MURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-7.48

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.87 indicates that MURA has no problem at all paying its short term obligations.

With a Current ratio value of 2.87, MURA is not doing good in the industry: 65.80% of the companies in the same industry are doing better.

MURA has a Quick Ratio of 2.87. This indicates that MURA is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of MURA (2.87) is worse than 63.22% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.87
Quick Ratio	2.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.06% over the past year.

EPS 1Y (TTM)17.06%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%5.38%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

MURA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.00% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y19.32%

EPS Next 2Y30.29%

EPS Next 3Y21.53%

EPS Next 5Y12%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MURA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MURA's earnings are expected to grow with 21.53% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.29%

EPS Next 3Y21.53%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MURA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MURAL ONCOLOGY PLC

NASDAQ:MURA (9/12/2025, 8:00:01 PM)

2.08

+0.01 (+0.48%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-04 2025-08-04/bmo

Earnings (Next)N/A N/A

Inst Owners57.85%

Inst Owner ChangeN/A

Ins Owners1.82%

Ins Owner Change-0.74%

Market Cap36.03M

Analysts77.78

Price Target6.12 (194.23%)

Short Float %1.43%

Short Ratio0.7

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-10.61%

Min EPS beat(2)-28.77%

Max EPS beat(2)7.55%

EPS beat(4)1

Avg EPS beat(4)-5.69%

Min EPS beat(4)-28.77%

Max EPS beat(4)7.55%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)20%

EPS NQ rev (1m)-9.27%

EPS NQ rev (3m)-8.92%

EPS NY rev (1m)-14.21%

EPS NY rev (3m)-14.21%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.61
P/tB	0.61
EV/EBITDA	N/A

EPS(TTM)-7.71

EYN/A

EPS(NY)-2.34

Fwd EYN/A

FCF(TTM)-7.51

FCFYN/A

OCF(TTM)-7.51

OCFYN/A

SpS0

BVpS3.39

TBVpS3.39

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-168.07%
ROE	-250.33%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-235.67%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	1.38%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.87
Quick Ratio	2.87
Altman-Z	-7.48

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)167.92%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)17.06%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%5.38%

EPS Next Y19.32%

EPS Next 2Y30.29%

EPS Next 3Y21.53%

EPS Next 5Y12%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y21.63%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year56.55%

EBIT Next 3Y25.54%

EBIT Next 5Y8.57%

FCF growth 1Y27.82%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y26.23%

OCF growth 3YN/A

OCF growth 5YN/A

MURAL ONCOLOGY PLC (MURA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens